Immunicum AB: Immunicum Announces Corporate Rebranding and Name Change to Mendus AB
Mendus Logo
- Rebranding reflects advancing pipeline in next generation cancer immunotherapies, upcoming manufacturing expansion, and long-term corporate aspirations
- The Company’s stock to continue trading under ticker symbol IMMU.ST on NASDAQ Sweden
Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on improving survival outcomes for cancer patients with tumor recurrence through cell-based immunotherapies, today announced that it has changed its corporate name from Immunicum AB to Mendus AB. The name change is effective as of today and is approved by the Swedish Companies Registration Office. The rebranding to “Mendus” reflects the Company’s maturing clinical pipeline and its broader positioning in cancer recurrence immunotherapy. In addition, this marks an important operational transition as the Company continues to mature with a longer-term focus on a global reach. The Company will continue trading under the ticker symbol “IMMU.ST” and the new website for Mendus AB is www.mendus.com.
“Today’s news marks an exciting step in a transformative period for the Company. Initiated with the merger and integration of Immunicum and DCprime and accelerated by subsequent directional pipeline decisions and promising novel R&D initiatives, these developments have resulted in a multi-faceted and broader long-term vision for the Company. The name Mendus captures our continued commitment to develop therapies that delay or reduce cases of cancer recurrence, while preserving the quality of life of people living with cancer,“ commented Erik Manting, PhD, Chief Executive Officer of Mendus. ”As we move forward in this new phase of important growth, we look forward to continuing our dedicated work in the development of safe and effective cell-based therapies that we believe can significantly decrease the chance of cancer relapse and improve overall survival.”
The Company received approval from its shareholders for the name change at the Annual General Meeting on May 10, 2022 and has since implemented the required legal and organizational changes. Mendus will continue to operate from its headquarters in Stockholm, Sweden, with an office in Gothenburg, Sweden and its main R&D center in Leiden, The Netherlands, which will be operating as a fully owned subsidiary Mendus BV. The Company’s stock ticker symbol will stay unchanged and Mendus AB will continue trading under the ticker symbol IMMU.ST at the Nasdaq Stockholm Main Market section.
In May 2022, the Company presented positive interim results from its ongoing ADVANCE II clinical study evaluating its most advanced proprietary development program, the cancer relapse vaccine DCP-001, as a maintenance therapy option in acute myeloid leukemia (AML). The trial is continuing follow-up of patients and Mendus expects to report on the status of key survival endpoints and immunomonitoring data in the fourth quarter of 2022. Mendus is preparing to advance the development of DCP-001 into a subsequent clinical study in AML maintenance and working to establish a scalable manufacturing infrastructure for the continued development of the program. The company also explores cancer relapse vaccination in ovarian cancer in an ongoing Phase I trial and is preparing for a signal-confirmatory trial in gastro-intestinal stromal tumors with its intratumoral immune primer ilixadencel. Mendus has established a broad collaboration network to further leverage its expertise in allogeneic dendritic cell biology to design novel immunotherapeutic approaches.
FOR MORE INFORMATION, PLEASE CONTACT:
Erik Manting
Chief Executive Officer
E-mail: ir@mendus.com
INVESTOR RELATIONS
Julie Seidel
Stern Investor Relations
Telephone: +1 212-362-1200
E-mail: julie.seidel@sternir.com
MEDIA RELATIONS
Mario Brkulj
Valency Communications
Telephone: +49 160 9352 9951
E-mail: mbrkulj@valencycomms.eu
ABOUT MENDUS AB (PUBL)
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. http://www.mendus.com/
Attachments
